Vestcor Inc Has $2.50 Million Holdings in Medpace Holdings, Inc. $MEDP

Vestcor Inc lifted its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 66.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,442 shares of the company’s stock after purchasing an additional 1,771 shares during the quarter. Vestcor Inc’s holdings in Medpace were worth $2,495,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the company. AQR Capital Management LLC grew its holdings in shares of Medpace by 65.1% during the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after purchasing an additional 404,226 shares in the last quarter. Wasatch Advisors LP grew its holdings in shares of Medpace by 14.0% during the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after purchasing an additional 116,354 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Medpace by 3.8% during the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock worth $374,836,000 after purchasing an additional 24,625 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Medpace by 18.9% during the 3rd quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock worth $276,313,000 after purchasing an additional 85,517 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Medpace by 92.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 347,049 shares of the company’s stock worth $194,920,000 after purchasing an additional 166,654 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Key Stories Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Multiple law firms, including Rosen, Pomerantz, Schall, Faruqi & Faruqi, and others, reiterated that a class action has been filed against Medpace alleging violations of federal securities laws and investor harm. Article Title
• Negative Sentiment: The lawsuits center on purchases made between April 22, 2025 and February 9, 2026, with investors urged to act before the June 8 lead-plaintiff deadline, keeping legal risk and uncertainty in focus. Article Title
• Neutral Sentiment: One item noted a management change, with Medpace elevating Brad Hansman to an executive operations role, but this appears to be a routine corporate update with no immediate market-moving detail. Article Title

Medpace Price Performance

Medpace stock opened at $454.25 on Monday. The company has a market capitalization of $12.97 billion, a PE ratio of 28.55, a price-to-earnings-growth ratio of 2.30 and a beta of 1.18. Medpace Holdings, Inc. has a one year low of $294.07 and a one year high of $628.92. The business has a 50 day simple moving average of $456.73 and a 200 day simple moving average of $508.39.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping the consensus estimate of $3.74 by $0.54. The business had revenue of $706.60 million during the quarter, compared to the consensus estimate of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.Medpace’s revenue was up 26.5% on a year-over-year basis. During the same quarter last year, the company earned $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities analysts anticipate that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

Insider Activity at Medpace

In related news, President Jesse J. Geiger sold 31,707 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the completion of the transaction, the president owned 15,000 shares in the company, valued at $6,829,500. This trade represents a 67.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the transaction, the general counsel owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. The trade was a 44.56% decrease in their position. The SEC filing for this sale provides additional information. 20.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Jefferies Financial Group raised Medpace from a “hold” rating to a “buy” rating and set a $560.00 price objective on the stock in a report on Friday, February 13th. Truist Financial decreased their price objective on Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a report on Wednesday, February 11th. BMO Capital Markets decreased their price objective on Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a report on Friday, April 24th. Barclays decreased their price objective on Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a report on Friday, April 24th. Finally, Weiss Ratings downgraded Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, April 6th. Four equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Medpace presently has an average rating of “Hold” and an average target price of $467.08.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.